Stock ECX EPIGENOMICS AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Epigenomics AG Xetra

Equities

ECX

DE000A11QW50

End-of-day quote Xetra
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
1.89 EUR -.--% Intraday chart for Epigenomics AG +8.31% -.--%
Mar. 14 Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EPIGENOMICS AG Stock Epigenomics AG
-.--% 1.52M -
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-17.60% 11.52B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+39.11% 3.27B
D+
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-20.67% 2.02B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-29.30% 1.44B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+11.45% 1.01B
B-
SEEGENE, INC. Stock Seegene, Inc.
-6.33% 719M
C+
CAREDX, INC Stock CareDx, Inc
-30.75% 418M
C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-51.02% 339M
C-
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
-2.58% 284M - -
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. ECX Stock
  4. ECX Stock
  5. Ratings Epigenomics AG